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1. Introduction
Venous thrombosis is a multifactorial disease frequently related to the interaction of genetic
and environmental risk factors. Testing for specific mutations in these patients helps to
determine the decision on the duration of anticoagulant therapy, risk stratification for primary
or secondary prophylaxis. Some of the recently discovered genetic risk factors, such as factor
V Leiden and prothrombin G20210A mutations, are quite common in the population. When
compared to functional assays, molecular assays provide clear results without different cut-
off values. Accordingly, laboratory investigation of thrombophilic disorders has expanded due
to incorporation of modern molecular assays. Criteria used to select specific DNA methodol‐
ogies reflect the issues of cost, automation, speed, reliability, and simplicity for specific
diagnostics. A variety of currently used molecular methods fulfill many, but not all of these
criteria. The new methods of real-time PCR and DNA microarrays offer the potential for
widespread application and utility in the future. Problems arise with interpretation in many
new polymorphisms without significant clinical relevance.
Let's look at the history of molecular diagnosis of thrombophilia. Since the very beginning of
the diagnosis of thrombophilic disorders, which arose from the study of families with a high
frequency of thrombophilic complications, it was apparent that in a number of cases, the
disorder was due to dominantly inherited conditions. Already the discovery of the first
families presenting a defect in antithrombin (AT) led to the description of the genetic causes
of this defect. As such, over 150 causes of AT mutation were described.
Molecular genetic methods were implemented into the screening examinations for thrombo‐
philic disorders in the 1990’s along with the first discoveries of coagulation inhibitors (AT,
protein C and protein S). The discovery of the molecular cause of activated protein C (APC)
resistance by Bertina in 1994 greatly expanded their utilization.
© 2013 Slavik; licensee InTech. This is an open access article distributed under the terms of the Creative
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Figure 1. Prevalence and risk of individual thrombophilic markers with a time line representing their discovery[1] De‐
spite the expansion of these methods, the following years brought forth discoveries of defects on a molecular basis,
which posed decreasing risks of thrombosis, as can be seen in Fig 1. However, until the end of the last century, it has
been assumed that further investigations of genetic causes of thrombophilia are needed to clarify the risk of this disor‐
der in a more detailed manner. Currently, it is apparent that there is a deflection from this idea and attention is fo‐
cused rather on the elucidation of the complex pathophysiology of coagulation at the molecular level.
Successive determination of relative risk of individual factors and their prevalence in the
population led to the gradual definition of the panel of genetic thrombophilia. Currently, they
can be divided into two groups i.e.1/ a well-defined genetic thrombophilic risk factors and 2/
potential risks factors of thrombophilia.Well-defined VTE risk factors include resistance to
activated protein C (APCR) often due to factor V Leiden (FVL), prothrombin G20210A gene
mutation (FII G20210A), high factor VIII (FVIII) activity or homocysteine level, and natural
anticoagulant deficiencies: antithrombin (AT), protein C (PC), and protein S (PS). Patients with
laboratory-confirmed thrombophilia are at greater risk for VTE, but most will never have such
an event[2]. VTE risk increases synergistically as other risk conditions are acquired (eg,
pregnancy, trauma, immobilization). More than 60% of patients with idiopathic (spontaneous
or unprovoked) VTE have inherited thrombophilia[3].
An individual’s risk for VTE would be determined by the combination of baseline propensity
for thrombosis and the magnitude of the acute insult. In the face of genetically increased
baseline hypercoagulability (major genetic thrombophilic state) even a relatively weak insult
(e.g., blood stasis during a flight) can be sufficient to precipitate DVT. Likewise, in an indi‐
Pregnancy Thrombophilia - The Unsuspected Risk2
vidual with a relatively low level of baseline genetic hypercoagulability (potential genetic
thrombophilic state) a relatively strong thrombogenic event (e.g., pregnancy) may be required
to provoke an episode of VTE[4]. Thus, the precipitating event in such individuals is often
clinically overt. In most cases, such thrombophilic individuals never suffer VTE throughout
their lifetimes, and when they do have an episode, it is unlikely to recur. In contrast, an
individual with a high level of baseline genetic hypercoagulability is at such high risk that
relatively minor acquired triggers can initiate a thrombotic episode. These triggers are
therefore subclinical, giving the appearance that the patient has “idiopathic”, “spontaneous”,
or “unprovoked” VTE.
Thrombophilia Prevalence* (%) Relative risk
Antitrombin deficiency 0.02 10
Protein C deficiency 0.2 - 0.4 10
Protein S deficiency < 1 10
FV Leiden (G1691A) homozygosity 0.02 50
FV Leiden (G1691A).heterozygosity 5-7 5 - 7
F II (G20210A) 2 - 7 2 - 3
Fibrinogen gamma 10034T 6 2
* prevalence in Caucasian population
Table 1. Prevalence and relative risk of venous thromboembolism associated with well defined major genetic risk
factors[5]
2. Major genetic thrombophilic states
Major genetic thrombophilic states include defects with clinically confirmed risk for VTE and
an understanding of the pathophysiological action of these defects.
2.1. Antithrombin
Egeberg first described familial antithrombin III deficiency, now termed antithrombin
deficiency, in 1965[6]-[8]. This first work already pointed out that antithrombin deficiency is
a significantly more serious risk factor for developing thrombosis than protein C and S
deficiency, and that the majority of patients show clinical manifestation before the age of 25[7],
[9]. This does not pertain to changes of the heparin binding site, which occurs frequently, and
does not present a risk in the heterozygous form[9].
Based on extensive studies, the thrombotic risk for patients with AT deficiency was determined
to be increased five-fold, based on the 1.1 % prevalcence of this deficiency in patients with
venous thrombosis compared to 0.2 % prevalence in the control group[10]. Other studies
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determined the prevalence of AT deficiency to be between 1 – 0.5 % [6]. There are two primary
types of antithrombin deficiency: type I and type II. Type I antithrombin deficiency is charac‐
terized by an inadequate amount of normal antithrombin present. In this case, there is simply
not enough antithrombin present to inactivate the coagulation factors. In type II antithrombin
deficiency, the amount of antithrombin present is normal, but it does not function properly
and is thus unable to carry out its normal functions. In many cases, the antithrombin in type I
deficiencies has a problem binding to heparin, although there have been multiple other
changes to the antithrombin molecule described.
Antithrombin deficiency may be assessed by chromogenic or clotting laboratory methods. The
chromogenic assay is the most simple and usually preferred. Overall, there are fewer con‐
founders with antithrombin activity assays than with protein C or protein S activity assays;
partly because chromogenic antithrombin activity assays are performed rather than clot-
based[11]. For antithrombin activity, chromogenic (IIa- or Xa-) based assays which are not
affected by heparin are available. Thrombin (IIa)-based assays, in theory, can be falsely
elevated by elevated heparin cofactor II because heparin cofactor II is a natural inhibitor of
thrombin. Factor Xa-based assays might be less sensitive to type II deficiencies than the IIa-
based assays[12]. Direct thrombin inhibitors falsely increase results in IIa-based assays but not
with Xa-based assays, because they inhibit factor IIa but not factor Xa[13].
A false-positive result for a type II deficiency may occur in the presence of a heparin-binding
site (HBS) mutation. Extending the incubation time of the activity assay to 300 sec may help
normalize results, since the extra time allows the assay to overcome this limitation and
normalize results, whereas other (clinically important) mutations remain abnormal[14]. In
general, HBS mutations are thought to be not significant except in homozygotes[14].
Another caveat with antithrombin testing involves different type II mutation called antith‐
rombin Cambridge II A384S[15],[16]. Heterozygotes and homozygotes with this mutation
were found to have normal activity in an anti-Xa assay (and appropriately low activity with
an anti-IIa-based assay). Heterozygosity was found in 0.1–0.2% of the general population and
0.4–1.7% of patients with venous thrombosis. Heterozygosity was associated with a ninefold
increased risk for venous thrombosis. The main disadvantage of screening for deficiency using
an antithrombin antigen assays is that type II (qualitative) deficiencies will not be detected.
2.2. Protein C
The first studies demonstrating increased risk of thrombosis in patients with heterozygous
protein C deficiency were presented in 1981[17],[18]. No difference between patients with
various types of deficiency (I or II) and basic mutation were noted. These studies showed that
a large majority of patients already has clinical manifestations of the disease at a young age[19].
In addition, it is interesting to note that in some patients, APC resistance was also present as
an additional factor increasing the risk of thrombosis[20].
The prevalence of protein C deficiency in patients with venous thromboembolism has been
determined to exist approximately 3%[21]-[23] compared to 0.2 % prevalence in the healthy
population[18]. When compared with the control group, the relative thrombotic risk for
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protein C deficiency is apprixomately 6.5 fold[24]. Despite the relatively low population
prevalence, the high risk of thrombogenicity results in a 1–2% contribution of protein C
deficiency on all thrombophilic conditions.
Protein C deficiency can be detected by chromogenic or clotting methods. Both assays may
have pitfalls in testing. Clot-based assays are aPTT- or Russell viper venom (RVV) based, either
of which can give falsely high results in the presence of direct thrombin inhibitors. With aPTT-
based assays, lupus anticoagulants can cause falsely high results and elevated factor VIII or
factor V Leiden can cause falsely low results. Heterozygous factor V Leiden did not appear to
affect an RVV-based assay, but artificially low protein C results in homozygous factor V Leiden
patients could not be excluded due in part to the small number of such patients[25]. Lupus
anticoagulants did not falsely increase protein C levels using an RVV-based assay[25], but
according to the manufacturer, the possibility of lupus anticoagulant interference cannot be
excluded.
There are two primary types of antithrombin deficiency: type I and type II. Type I antithrombin
deficiency is characterized by an inadequate amount of normal antithrombin present. In this
case, there is simply not enough antithrombin present to inactivate the coagulation factors. In
type II antithrombin deficiency, the amount of antithrombin present is normal, but it does not
function properly and is thus unable to carry out its normal functions. In many cases, the
antithrombin in type I deficiencies has a problem binding to heparin, although there have been
multiple other changes to the antithrombin molecule described. None of these conditions affect
chromogenic assays, but there is a rare type II variant that might not be detected by chromo‐
genic assays but is detected by clot-based assays. More recently, another rare variant, Asn2Ile,
has been identified that is missed by chromogenic assays, and it is also missed by some clot-
based assays[26]. Testing protein C while on warfarin therapy is not recommended because
warfarin decreases protein C (and protein S) levels. However, if testing is inadvertently sent
while on warfarin, the result with a chromogenic assay is typically higher than with clot-based
assays.
2.3. Protein S
Protein S is an important anticoagulant protein, which acts as a non-enzymatic co-factor of
activated protein C (APC) during inactivation of factor Va and VIIIa. Laboratory screening of
protein S deficiency is complicated by the fact that protein S circulates in bloodstream in two
forms, i.e. bound and free[27]. Forty percent of total protein S is represented by free protein S,
which acts as the APC co-factor.
Protein S deficiency may be divided into three basic forms. Type I is characterized by a decrease
in total protein S most often due to decreased synthesis, type II is characterized by decreased
protein S activity and type III by a decreased level of free protein S and normal activity of total
protein S.
Most deficits are type I or a combination of types I and III. At present very few cases of type
II protein S deficiency have been described. The prevalence of protein S deficiency represents
1-2% of patients with deep venous thrombosis and 6% of families with thrombophilia. From
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a genetic viewpoint, 70 different mutations in the gene for protein S have been described to
date.
The detection of protein S deficiency is complicated, because protein S circulated in the blood
stream in two forms, i.e. bound protein S associated with C4b binding protein (60%) and free
protein S (40%). The thrombotic risk potential constitutes only free protein S. Protein S activity
may be determined using clot-based (aPTT, PT, Xa or RVV) assays. A number of factors may
interfere with clot based assays. Lupus anticoagulants or direct thrombin inhibitors[28] can
cause falsely elevated results. Factor V Leiden can cause falsely low results with PT-, Xa-, RVV-,
and some aPTT-based assays[29]-[31]. With aPTT-based assays, elevated factor VIII can cause
falsely low results because factor VIII shortens the aPTT in the assay.
Protein S free or total antigen assays do not suffer from similar limitations. Acute phase
reactions (e.g., illness, inflammation) can falsely decrease protein S in vivo, and it is a common
cause of low protein S activity or decreased free antigen results (but not total protein S antigen).
This effect is attributed to C4b-binding protein, which becomes elevated during acute phase
reactions. C4b-binding protein binds to protein S, thus reducing the amount of free protein S.
When protein S is bound to C4b-binding protein, it is essentially inactive. The main disad‐
vantage of free or total protein S antigen assays is that type II deficiencies will not be detect‐
ed[32], but the majority of hereditary protein S deficiencies are type I (quantitative).
3. Factor V Leiden and APC resistance
The detection of Factor V Leiden (FVL) is usually performed as genetic confirmation of
activated protein C (APC) resistance positivity. The classical assay for activated protein C
resistance detects a ratio between a baseline activated partial thromboplastin time (aPTT) and
the aPTT with APC. A variety of conditions can cause "falsely elevated" or "falsely decreased"
ratios and interfere with this test, rendering it somewhat insensitive and nonspecific for
diagnosing FVL, However, a positive result of APC resistance, due to acquired factors, may
pose the same risk as the presence of the FVL mutation [33].
Elevated factor VIII (FVIII), the presence of a lupus anticoagulant, and certain drugs including
oral contraceptives, estrogen, vitamin K antagonists, heparin, or direct thrombin inhibitors
may interfere with the traditional aPTT-based APC assay. Improved assays are available,
including the second-generation assay for activated protein C resistance, with sensitivity and
specificity approaching 100% for the diagnosis of factor V Leiden[34]. The modification
involves diluting the patient plasma into factor V-deficient plasma, thus minimizing the effect
of factor V deficiencies and factor FVIII elevations that alter the baseline aPTT. Despite these
changes, lupus anticoagulants may cause falsely low ratio results and direct thrombin
inhibitors can cause falsely normal ratio results[35],[66].
Newer test options include Russell viper venom (RVV)-based assays, which uses the factor X
activator from RVV. The reagent contains phospholipid designed to reduce lupus anticoagu‐
lant interference.
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A factor Xa-based clotting assay is a third type of new assay for APC resistance. The method
includes dilution into a proprietary reagent containing purified factors II, fibrinogen, protein
S, and activated protein C. The inclusion of these factors presumably eliminates interference
due to deficiencies or increased levels of these proteins.
While APC resistence positivity caused by presence of lupus anticoagulants is often considered
to be „falsely elevated“, several studies report that this parameter has some clinical signifi‐
cance.
While APC resistance positivity caused by lupus anticoagulants is often thought of as an
"falsely elevated", some studies report that it have clinical significance.
Factor V Leiden can be detected by several DNA assays. In recent years, different molecular
approaches, including restriction fragment length polymorphism (RFLP) and real-time PCR,
have been developed to genotype single nucleotide polymorphisms (SNPs). Compared with
more traditional methods such as RFLP, real-time PCR is a fast, simple, and accurate procedure
for SNP genotyping of medium to large collections of samples. Real-time PCR analysis can be
performed using various strategies[5]. In the hydrolysis assay, the probe and fluorescent
chromogen is released by hydrolysis during PCR amplification and the free probe quantity is
proportional to the fluorescence[37]. Fluorescence resonance energy transfer (FRET) is a
method that distinguishes alleles by melting the products and monitoring the loss of fluores‐
cence using an allele-specific oligonucleotide probe which hybridizes to specific sequen‐
ces[38]-[40].
High-resolution melting analysis with LCGreen™ I is a newly designed analysis that de‐
tects heteroduplexes during homogeneous melting curve analysis with a new fluorescent
DNA  dye[41].  Genotyping  of  single-nucleotide  polymorphisms  (SNPs)1  by  high-resolu‐
tion melting analysis in products as large as 544 bp has been reported. This allows closed-
tube, homogeneous allele-specific PCR genotyping [45],[46], on real-time PCR instruments
without fluorescently labeled probes[42]-[44]. Heterozygotes are identified by a change in
melting curve shape, and different homozygotes are distinguished by a change in melting
temperature  (Tm).  However,  it  is  still  not  clear  whether  all  SNPs can be  genotyped by
this method[45]-[47].
Among the Caucasian population,  factor  V Leiden (factor  V 1691G-A) is  the most  com‐
mon genetic defect causing thrombosis[48]-[54]with a frequency between 2 and 15 % [49]..
Factor  V mutation was first  described by Bertina et  al  in  1994 at  the University of  Lei‐
den[55],  based  on  the  discovery  of  resistance  to  activated  protein  C  (APC),  which  was
first described in 1993[56]. The heterozygous form of factor V Leiden increases the risk of
thrombosis 3 – 8x [49],[57],[58], while the homozygous form presents a risk which may be
up to 80 times greater[59].
Factor V Leiden is present in up to 20% of patients with venous thrombosis[50],[57] and in
over half of probands in selected families with thrombophilia making it the most common
genetic abnormality in patients with thrombosis.
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4. Pathophysiology of action FV Leiden mutation
FV plays a key role in both the procoagulation and anticoagulation cascade processes. In the
activated form, it acts as a co-factor for FXa in the prothrombinase complex and as such
catalyses the conversion of prothrombin to thrombin. In the inactive form FV acts as an APC
co-factor in the regulatory activity of FVIIIa. In inherited and acquired defects, this double role
allows FV to influence the manifestation of these disorders into hemorrhagic or thrombotic
forms [60],[61]. To determine this manifestation, it is necessary to recognize precisely the
procoagulation and anticoagulation forms of FV[63].
Figure 2. Schematic representation of the structure of FV
Unlike FV, FVa increases the FXa activated conversion of prothrombin in the prothrombinase
complex. It may be expected that the cleaved B-domain allosterically inhibits the binding of
FV in the active site of FXa [63].
The mechanism by which FVa acts on FXa is not completely understood. Based on the latest
works, it may be assumed that FVa increases the binding affinity of FXa to phospholipids by
about 100x. In addition, it was determined that FVa in the prothrombinase complex does not
change the binding site of FXa, but instead increases the affinity of the prothrombinase complex
to prothrombin and ensures an increase in binding sites.
The co-factor activity of FVa is balanced by APC, which proteolytically cleaves FVa at the
Arg306, Arg506 and Arg679 sites of the heavy chain. The weakest inactivation is seen during
cleavage at the Arg679 site. Latest discoveries suggest two pathophysiological models of FVa
cleavage. The first model assumes preferential cleavage at the Arg506 site followed by cleavage
at the Arg306 site. Alternatively, FVa may be inactivated directly by cleavage at the Arg306
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site. Cleavage at the Arg506 site also decreases the affinity of FVa to FXa, while cleavage at the
Arg306 site causes complete inactivation of FVa [64].
5. Anticoagulation function of FVa
Aside from its procoagulation function, FVa also possesses an anticoagulation function, which
is expressed as APC activation. In this case it is a cofactor in the proteolytic cleavage of
FVIIIa[65]. Recent experimental works supports this model where the addition of purified FV
renewed the function of APC in both healthy patients and in families with the Leiden mutation.
The experiments utilized measured generation of thrombin.
Figure 3. Anticoagulation structure of FV[59]
Thus if the anticoagulation function of FV is required, cleavage must occur in position Arg506.
Unlike APC mediated cleavage in sites Arg306 and Arg679, which does not exhibit anticoa‐
gulation activity.
6. FV and thrombophilia
Such described pathways of FV activation point to the balance of pro- and anticoagulation
activity of factor V and its significance in maintaining haemostatic equilibrium. The pathways
of FV activation describe the mututal balance of both pro- and anticoagulation activity of factor
V and its significance in maintaining haemostatic equilibrium.
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APC resistance is an in vitro described phenomenon, which is characterized by a slight
anticoagulation response to APC in plasma. Such decreased sensitivity to APC leads to
inadequate regulation of thrombin production. As such, APC resistance is associated with an
increased risk of developing thrombosis. APC resistance is associated with FV Leiden mutation
in up to 90 % of cases.
FV Leiden mutation significantly influences the pro- and anticoagulation balance of FVa. The
Leiden mutation, which leads to the disappearance of the Arg506 cleavage site, causes an
insufficient decrease of the procoagulation activity of FVa, which explains the presence of
procoagulation states in carriers of the Leiden mutation.
Figure 4. A schematic illustration of the activation of FV to procoagulation and anticoagulation forms
The discovery of a second pathway of action of FVa, where via APC it acts as a co-factor during
proteolytic cleavage of FVIIIa aids us in establishing the effect of the Leiden mutation. Since
FV with the Leiden mutation does not contain a cleavage site in the position Arg506, the
anticoagulation form FVac cannot be produced and therefore there is only weak co-factor
activity of APC during FVIII proteolysis.
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7. Prothrombin 20210A
Mutations in the 3´- untranslated region of the prothrombin gene in the position 20210 G-A
are associated with an increased level of prothrombin and as such present an increased risk of
developing thrombosis[66]. This mutation was described with a high prevalence (up to 18%)
in families with thrombosis and in 6.2% of patients with first thrombosis[66].
F II 20210G-A mutation in the gene for prothrombin was found through linkage analysis in
families with a history of venous thrombosis and no other congenital or acquired thrombophil‐
ic risk factors[67]. The mutation is located in the 3 'gene region, which already does not over‐
write to the protein. The mutation is located in the 3 'gene region, which already does not
overwrite to the protein. Therefore, it appears difficult to develop a specific functional coagula‐
tion tests based FII activity determination. However, in large clinical studies found significant‐
ly elevated levels of prothrombin mutations in patients with FII 20210 GThere is no evidence
that the homozygous mutation carriers have a higher level of prothrombin than heterozygous.
The pathophysiologic influence of the mutation is not yet fully explained. The original view
was that the mutation alters the conformation of the pre-mRNA 3'UTR, which has an increased
affinity for the production of polyA end. This causes an increased concentration of mRNA with
an increase in protein synthesis, so the greater the level of prothrombin in plasma[68]. Later
work demonstrated that the mutation does not affect the mRNA level, but instead 3' cleavage/
polyadenylation, which affects abnormal properties of mRNAs[69]. Finally, recent work show‐
ing abnormal properties mRNA 20210A mutation in the 3'UTR, which cause the emergence of
polyA preferentially in the presence of this mutation in the mRNA[70].
The prevalence of this mutation in the normal population is 1.7% in northern Europe and 3%
in southern Europe[71],[72]. This mutation is very rare among people of African and Asian
origin. It was found that originated as a founder effect until after the separation of Caucasian
populations [73]-[76].
Apart from this, the mutation may represent an additional risk factor for spontaneous abor‐
tions especially during the first trimester[77]. The risk of venous thrombosis is significantly in‐
creased in women with prothrombin mutation during pregnancy and after childbirth,and the
frequency of thrombosis further increases in the presence of an additional risk factor, which -
among others - can be factor V Leiden[78]. Prothrombin mutation may also affect the risk of ar‐
terial thrombosis, but this has not been clearly demonstrated yet. In a large group of 3028
patients, a statistically significant relationship between the mentioned mutations and ischemic
stroke (odds ratio 1.44) [79] was demonstrated. Ingeneral the risk of spontaneous recurrent
thromboembolic events is the same in patients with mutations without such mutations[80].
8. Potential genetic thrombophilic states
8.1. Plasminogen activator inhibitor-1 mutation
The plasminogen activator inhibitor-1 (PAI-1) mutation is a single base insertion or deletion
at position -675 (4G/5G) in the promoter region of the PAI-1 gene, which is associated with
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higher levels of PAI-1 transcripts and also higher plasma activity of PAI-1[81]. In the PAI-1 -
675 4G/5G mutation, the 4G site binds an enhancer element only, whereas the 5G allele binds
both enhancer and suppressor elements. As a result individuals with 4G/5G or 4G/4G geno‐
types have an increased level of transcription and consequently a higher PAI-1 protein level
than individuals with 5G/5G polymorphism. Because PAI-1 is a rapid inhibitor of tissue
plasminogen activator (t-PA), the 4G/5G variant of mutation can increase the activity of PAI-1
and decrease the conversion of plasminogen to plasmin, which causes decreased fibrin
degeneration and increased clot stabilization.
Under physiological conditions, PAI-1 is released into the circulation and the extracellular
space by only a few cells: liver cells, smooth muscle cells (SMC), adipocytes, and platelets are
the major sources of PAI-1. This results in plasma levels of only 5–20 ng/ml of active PAI-1,
sufficient to control fibrinolysis and extracellular proteolysis.
Under pathological conditions, however, several other tissues secrete quite large amounts of
PAI-1: tumor cells, endothelial cells in response to inflammatory cytokines, and other inflam‐
mation-activated cells. High PAI-1 plasma levels are consistently found in patients with severe
sepsis but also with other acute or chronic inflammatory diseases such as atherosclerosis. PAI-1
is upregulated by inflammatory cytokines and may therefore be regarded as a marker for an
ongoing inflammatory process. It is of major importance, however, that no classic inflamma‐
tory response element was found in the PAI-1 promoter region, and it is still unclear how PAI-1
expression is upregulated during inflammation[82].
8.2. Fibrinogen
Fibrinogen is a 340-kDa glycoprotein produced in the liver with a plasma concentration of 180
- 450 mg/dl. It consists of two monomers linked by a disulfide bond. Each monomer consists
Figure 5. Schematic action PAI-1 in regulation mechanism of fibrinolytic system
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of three polypeptide chains encoded by three distinct genes: Aa, Bb and γ. It binds to the
platelet through the glycoprotein IIb/IIIa receptor and, therefore, is highly involved in the
thrombotic processes. It also has a direct effect on the vascular wall and blood viscosity. An
association between increased circulating levels of fibrinogen and the development of arterial
thrombosis has been demonstrated[83],[84]. The mechanisms that explain the association
between increased fibrinogen and AMI include increased fibrin formation, increased blood
viscosity, platelet hyperaggregability and an increased proliferation of vascular endothelial
and smooth muscle cells[85]. In addition, fibrinogen is an acute phase reactant and possibly
an indicator of chronic inflammation associated with atherosclerosis.
There are several polymorphisms identified in the genes that code the three polypeptide chains
and are associated with increased concentration of circulating fibrinogen (>500 mg/dl). From
the functional point of view, the most relevant are those in the β chain: Arg448Lis, -148 C/T,
-455 G/A and 854 G/A, with the last two having the most pathophysiological interest due to
their association with the development of vascular disease. The genotype -455A is present in
10-20% of the general population and is correlated with an increase of 10% high concentration
of fibrinogen, prevalence of other mutations not specifically described in current literature.
Some studies[86] showed an association between the -455 polymorphism and an increased risk
for arterial thrombosis.
9. Coagulation factor VII (FVII)
Factor VII is a single polypeptide chain, 406-amino acid glycoprotein with a weight of ~50,000
Da. It is vitamin K dependent protein, synthesized in the liver and has a plasma concentration
of 500 ng/mL. FVII is transformed into its activated form (FVIIa) by binding with tissue factor
(TF). The TF:FVIIa complex converts Factor IX and Factor X to their active forms, FIXa and
FXa. Recent studies have described an association between an increased plasma concentration
of FVII and development of arterial thrombosis[87]
In contrast, polymorphism Arg (R) 353Gln (Q) in the FVII gene is associated with a 20-25%
decreased plasma concentration of FVII.[88]
In addition, several studies[89],[90] have demonstrated that plasma concentration of FVII is
lower in subjects homozygous for the 353Gln allele compared with those homozygous for the
353Arg allele.
In contrast, other studies have been unable to corroborate the association of the polymorphism
R/Q353 with AMI or increase in plasma concentration of FVII in subjects with Arg/Arg
genotype[91].
10. Polymorphisms in platelets
Platelets play an important role in the development of acute coronary syndromes. Platelets
possess glycoprotein receptors on the surface membrane which participate in platelet activa‐
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tion, degranulation and aggregation. These receptors belong to the family of integrins (aIIb
β3) and are highly polymorphic, which often produces an antigenic alteration of the glyco‐
protein. The most frequent polymorphisms present in these glycoproteins are receptors for
von Willebrand factor (vWF) (GPIb-IX, GIIb-III), a in the protein receptor for collagen (GPIa-
IIa), and in the receptor for fibrinogen (GPIIb-IIIa).
The most abundant glycoprotein on the platelet membrane is the GPIIb-IIIa complex. Inacti‐
vated platelets bind through GIIb-IIIa complex to vWF and to fibrinogen. This polymorphism
consists of a thymine substitution for cytosine in the 1565 position in exon 2 of the GPIII
gene[92]. Approximately 25% of the population of northern Europe is a carrier of at least one
allele PLA2 (PLA1/A2). Several studies described an association between this polymorphism
and AMI in patients <60 years[93], ACS[94] and atherothrombosis[95]. Many studies have
attempted to establish an association between the presence of allele PLA2 and coronary artery
disease, but results are still contradictory.
11. Hyperhomocysteinemia
Increased levels of homocysteine are associated with an increased risk of thrombosis[96]-[98].
Two studies performed on an undivided group of patients showed that a level above 18.5
µmol/l in 5 % (10 % respectively) of tested subjects led to a two-fold increase in the risk of
thrombotic episodes[99]-[101]. This means that hyperhomocysteinemia represents 5 – 10 % of
all thrombotic episodes.
Hyperhomocysteinemia may develop due to genetic or acquired dispositions[99]. Acquired
dispositions primarily include low vitamin intake or resorption (B6, B12, folic acid), which
leads to an increase in homocysteine level[101],[102]. Genetic factors include the very rare
cystathione β-synthase deficit, whose homozygous form represents classical hyperhomocys‐
teinemia with very high levels[103], and on the other hand the very common variant of the
methyltetrahydrofolate reductase (MTHFR) gene, which leads to the thermolabile enzyme
variant with a slightly increased homocysteine level[104]-[106]. Currently, direct association
between the MTHFR 677TT variant, increased homocysteine level and risk of developing
thrombosis is not distinctly established[107].
12. Conclusion
The elucidation of the precise pathogenesis of action leads to the conclusion that to explain the
clinical expression of thrombophilic conditions, it is most important to understand the
interaction of at least one genetically dependent thrombophilia with one or more acquired
conditions.
Determination of thrombophilic markers is necessary to evaluate the risk of thrombophilia in
the examined patients. The degree of risk depends largely on the choice of methods for testing
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individual markers and their specificity. Another important reality in the interpretation of tests
are interfering factors for each test.
Uncritical interpretation of laboratory results can lead to misdiagnosis and thrombophilia
testing exemplifies this. If possible errors and overdiagnosis are to be avoided, the following
points should be respected: Normal ranges for antithrombin and proteins C or S levels are
wide and patients with deficiency may have levels that are only slightly below normal.
Repeated testing is often required for diagnostic accuracy. For example, laboratory quality
assurance data have shown that for protein S in particular the rate of laboratory error in
diagnosis can be as high as 20%. Pregnancy induces a state of resistance to the anticoagulant
effect of activated protein C, which mimics the presence of factor V Leiden. Pregnancy and
OCP use lead to a fall in plasma protein S concentration. Antithrombin concentration is
reduced in acute thrombosis, by heparin treatment and in pre‐eclampsia state. Proteins C and
S are vitamin K dependent and their concentrations are reduced by warfarin treatment. Even
if the above potential pitfalls are avoided, there is no indication to routine testing for heritable
thrombophilia at presentation with acute VTE, as clinical management is not influenced by the
results.
Concerning the determination of mutation FII 20210 G / A, the situation is quite the opposite.
Screening test shows high interference with the current status, therefore it is completely
unusable and direct molecular genetic analysis of point mutations FII 20210 G-A.
The identification of potential genetic causes of thrombophilia, such as mutation of fibrinogen,
platelet receptor, PAI-1, F VII and homocysteine are designed for testing the rare causes of
thrombophilia in thrombotic centers. Howeever, they can be beneficial to clarify complex cases
of thrombophilia especially if associated with repeated manifestations in the family.
Genetic testing is a separate part of the diagnosis of thrombophilia. Generally, it is not intended
for screening the universal population, but only to determine the causes of thrombophilia in
defined groups of patients - young patients with a positive family history of thrombophilia,
in patients with previous thrombosis under 45 years of age, patients with the manifestation of
thrombosis in an unusual site (e.g. portal vein), and at women in pregnancy or with using oral
contraceptives.
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